PENNINGTON, N.J., June 18, 2024 /PRNewswire/ -- Zynext Ventures USA LLC (Zynext Ventures), the Venture Capital (VC) arm of Zydus...
New Spanish Website Aims to Educate and Empower Patients, Caregivers, and Healthcare Professionals to Make Informed Health Decisions BETHESDA, Md.,...
TORONTO, ON / ACCESSWIRE / June 18, 2024 / Theralase® Technologies Inc. ("Theralase®" or the "Company") (TSXV:TLT)(OTCQB:TLTFF), a clinical stage...
BOSTON, June 18, 2024 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX, “Elicio Therapeutics” or “Elicio”), a clinical-stage biotechnology company...
ABINGDON, United Kingdom, June 18, 2024 (GLOBE NEWSWIRE) -- Emergex Vaccines Holding Limited (‘Emergex’, or the ‘Company’), a clinical-stage biotechnology company...
OXFORD, England and CAMBRIDGE, Mass., June 18, 2024 /PRNewswire/ -- SpyBiotech, a biotechnology company with a novel vaccine platform technology...
A 67% objective response rate (ORR) is reported in the publication summarizing results from the Phase 1 study assessing Evaxion’s...
Vancouver, British Columbia--(Newsfile Corp. - June 17, 2024) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or...
mRNA-1283 met its primary vaccine efficacy endpoint in a Phase 3 trial, demonstrating non-inferior vaccine efficacy against COVID-19 compared to...
Majority of patients continue to be followed for survival with multiple patients approaching 3 years Median Overall Survival (mOS) remains...
Velocity President and Chief Executive, Dr Paul Evans Velocity President and Chief Executive, Dr Paul Evans DURHAM, N.C., June 12,...
Clinical trial to evaluate the safety and efficacy of OBI-992 in advanced solid tumors.TAIPEI, Taiwan, June 12, 2024 (GLOBE NEWSWIRE)...
TORONTO, ON / ACCESSWIRE / June 10, 2024 / Theralase® Technologies Inc. ("Theralase®" or the "Company") (TSXV:TLT)(OTCQB:TLTFF), a clinical stage...
mRNA-1083 met its primary endpoints, eliciting higher immune responses against influenza virus and SARS-CoV-2 than licensed flu and COVID vaccines...
Vancouver, British Columbia--(Newsfile Corp. - June 10, 2024) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC), ("Defence" or...
Manufacturing is underway and doses of Moderna's Spikevax 2024-2025 formula will be ready to ship as early as August, pending...
Independent health agency continues to attract industry’s brightest minds; fortifies teams companywide as part of commitment to delivering industry-leading innovation,...
Manufacturing of instruments, consumables and reagents for cell and protein analysisConsolidation of existing sites and functions in Ann ArborOverall investment...
Center for Biologics Evaluation and Research has chosen mRNA-3705 as one of four investigational medicines for accelerated development to address...
Company expects to lock database in June andremains on track to report key outcomes later in July. Pepinemab targets astrocyte...